EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma

Yizhou Huang, Maohui Chen iD, Zhenyuan Yang, Bingqiang Cai, Yongcong Zhang, Hongjin Wang iD, Shuliang Zhang, Taidui Zeng, Chun Chen iD, Bin Zheng iD

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70392 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Yizhou Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Immunotherapy, Muscle, Skeletal. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Center for Thoracic Tumours of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low skeletal muscle index (SMI) may identify host vulnerability in patients receiving intensive cancer therapy. However, its association with treatment tolerance and outcomes during neoadjuvant immunochemotherapy (nICT) for oesophageal squamous cell carcinoma (OSCC) remains unclear.

Methods

This multicentre retrospective cohort included 461 patients with locally advanced OSCC who initiated nICT between 2020 and 2023; 404 underwent oesophagectomy. Pretreatment SMI at the third lumbar vertebra was measured by two blinded radiologists. Low SMI was defined using sex‐specific outcome‐derived cutoffs, with sensitivity analyses using published thresholds. Neoadjuvant treatment tolerance grade (NAT‐TG) was used as a composite measure of treatment tolerance and feasibility, integrating treatment modification and failure to undergo curative surgery.

Results

Among 461 patients (mean age, 61.2 ± 7.3 years; 21.3% female), low SMI was present in 121 (26.2%) and was independently associated with an unfavourable NAT‐TG composite (NAT‐TG2–3 vs. NAT‐TG1; adjusted OR, 2.48; 95% CI, 1.62–3.82; p < 0.001). The association persisted after excluding six progression‐related surgical omissions (adjusted OR, 2.51; 95% CI, 1.59–3.95; p < 0.001). The overall distribution of treatment‐related adverse event severity differed between groups ( p = 0.012), with grade ≥ 3 events occurring in 36.4% of patients with low SMI and 22.9% of those without low SMI. In the surgical population, low SMI was independently associated with severe postoperative complications (adjusted OR, 2.92; 95% CI, 1.51–5.63; p = 0.001). During a median follow‐up of 43 months, 165 deaths occurred. The 1‐year mortality rate in the intention‐to‐treat population was 8.5% (95% CI, 5.9%–11.0%). In the primary intention‐to‐treat model, low SMI was associated with poorer overall survival (adjusted HR, 2.36; 95% CI, 1.67–3.33; p < 0.001). Associations were also observed for surgical overall survival (adjusted HR, 1.91; 95% CI, 1.31–2.80) and disease‐free survival (adjusted HR, 1.57; 95% CI, 1.11–2.22). Results were generally consistent when published SMI thresholds were applied.

Conclusions

Pretreatment low SMI was associated with less favourable nICT tolerance and feasibility, a higher incidence of severe postoperative complications and poorer survival. CT‐derived skeletal muscle assessment may complement baseline risk stratification, while intervention strategies require prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapyMuscle, SkeletalNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective Studies

Stichwörter der Autor:innen

low skeletal muscle massneoadjuvant immunochemotherapyoesophageal squamous cell carcinomaprognosisskeletal muscle indextreatment tolerance

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
  • Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, China.
  • National Key Clinical Specialty of Thoracic Surgery, Fuzhou, China.
  • Clinical Research Center for Thoracic Tumors of Fujian Province, Fuzhou, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Fujian, China.
  • Department of Thoracic Surgery, Quanzhou First Hospital, Fujian, China.

ORCID-Profile: Maohui Chen, Hongjin Wang, Chun Chen, Bin Zheng

Förderung

  • Clinical Research Center for Thoracic Tumours of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Huang, Y., Chen, M., Yang, Z., Cai, B., Zhang, Y., Wang, H., Zhang, S., Zeng, T., Chen, C., & Zheng, B. (2026). Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70392

Vancouver

Huang Y, Chen M, Yang Z, Cai B, Zhang Y, Wang H, et al. Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70392

BibTeX
@article{Huang2026,
  author = {Huang, Yizhou and Chen, Maohui and Yang, Zhenyuan and Cai, Bingqiang and Zhang, Yongcong and Wang, Hongjin and Zhang, Shuliang and Zeng, Taidui and Chen, Chun and Zheng, Bin},
  title = {Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70392}
}
Kostenlos starten →